Axonis Therapeutics Raises $115 Million in Series A Funding

Axonis Therapeutics, a biotechnology company focused on developing medicines targeting KCC2, successfully raised $115 million in an oversubscribed Series A financing round. The funding will be used to progress their lead development candidate, AXN-027, through clinical proof-of-concept trials in patients. AXN-027 is an innovative oral small molecule that aims to modulate KCC2, a key CNS chloride transporter essential for inhibitory neurotransmission, for treating epilepsy and pain. Additionally, the proceeds will further Axonis's efforts in developing next-generation compounds addressing other conditions such as psychiatric and neurodevelopmental disorders. Axonis leverages groundbreaking discoveries from institutions like Boston Children’s Hospital, Harvard, and Université Laval, and benefits from support by various grants and awards. The financing round was advised by the Goodwin Life Sciences team, which played a crucial role in the transaction.